Abstract: Chronic intestinal pseudo-obstruction (CIPO) is a rare disorder characterized by an impairment of coordinated propulsive activity in the gastrointestinal (GI) tract, which clinically mimics mechanical intestinal obstruction. CIPO is the most severe and debilitating form of GI dysmotility. CIPO may be primary or be secondary to pathology at any level of the brain-gut axis as well as systemic disease. The clinical features of CIPO are pleomorphic and largely depend on the site and extent of the segment of the GI tract involved. The diagnostic approach includes the need for investigations to exclude mechanical GI obstruction, screening for causes of secondary CIPO and the identification of the disease phenotype as well as the prompt recognition and treatment of complications such as malnutrition and small intestinal bacterial overgrowth. In managing this disorder, a holistic, multidisciplinary approach is needed with judicious use of pharmacotherapeutic agents. While currently there are no specific therapeutic modalities for CIPO, treatment is largely directed at maintaining adequate nutrition and electrolyte balance and enhancing coordinated GI motility. Surgery should be avoided unless advisable for carefully selected patients and may include stoma formation. This narrative review provides a concise overview of the literature on this rare, severe and complex disorder, and highlights the need and areas for further research to improve both diagnostics and therapeutics.
C hronic intestinal pseudo-obstruction (CIPO) is a rare disorder characterized by impaired propulsive motility within the gastrointestinal (GI) tract. 1 The impairment of GI motility in CIPO is severe enough to produce clinical features similar to mechanical intestinal obstruction, despite the absence of an obstructive pathology. CIPO represents a group of heterogenous disorders with multiple pathoetiologies. CIPO can arise in any part of the GI tract, although the small intestine and colon are the most affected segments. As such, clinical features are diverse and symptoms are markedly variable according to the disease location and burden along the GI tract. 2 CIPO is the most serious form of GI dysmotility and is associated with a significant morbidity and mortality. CIPO has a progressive course, is associated with widespread GI involvement, and its main complication is malnutrition. 3 Similar to other rare diseases whose symptoms are pleomorphic, and whose diagnostic criteria are poorly defined, CIPO too poses a clinical challenge as clinicians often fail to recognize it or mistake it with other functional GI disorders until its advanced stages. Thus, estimates of the prevalence of CIPO are difficult to accurately ascertain. Nationwide epidemiologic surveys in Japan have estimated the population prevalence of CIPO to be 3.7 per million in children 4 and 8 to 10 per million in all ages. 5 However, these are likely to be underestimates of the true prevalence owing to under-diagnosis of CIPO as there is a reported median delay of 8 years from symptom onset to CIPO diagnosis. 6 CIPO may manifest at any age but disease onset typically occurs in childhood or in young adulthood. 7 Approximately 100 infants are born with congenital CIPO every year in the United States. 8 Studies investigating the natural history of CIPO have identified a generally poor prognosis; with patients frequently undergoing multiple (often unnecessary) surgical procedures and requiring parenteral nutrition (PN). 6, 9 Case series have reported high mortality rates, especially in infants with CIPO, although exact figures are difficult to ascertain due to heterogeneity in reported results. 6, 10, 11 CIPO remains an under-diagnosed condition and current treatment options are suboptimal and largely supportive. The aim of this review is to provide a concise overview of the underlying pathophysiology, clinical features, diagnostic, and management approaches currently available for CIPO. In addition, we will identify potential areas for future research.
ETIOLOGY AND PATHOPHYSIOLOGY
Rather than referring to a singular pathophysiological process, CIPO is a term which covers a heterogenous group of patients where there is an impairment of GI motility. The etiology of CIPO can be broadly considered as primary (or idiopathic), secondary or familial 2, 7 (Fig. 1) . By definition, primary CIPO has no demonstrable etiopathologic cause. Secondary CIPO may be due to systemic pathology and is more commonly seen in older patients. 1 Examples of secondary causes of CIPO include endocrine disorders such as diabetes, hypothyroidism or hypoparathyroidism, connective tissue disorders such as Ehlers-Danlos syndrome, systemic sclerosis, paraneoplastic syndromes, autoimmune diseases such as celiac disease, drugs such as opioids, Chagas' disease and postinfectious epiphenomenon. 12 In addition, secondary CIPO can result from intrinsic pathologies in the central or enteric nervous system (ENS), such as cerebrovascular events. Familial forms of CIPO have been described which can be autosomal dominant, autosomal recessive, and X-linked and are comprehensively reviewed by Di Nardo et al. 13 Disruptions in smooth muscle cells (myopathy), interstitial cells of Cajal (mesenchymopathy), intrinsic intestinal innervation and/or extrinsic autonomic innervations (neuropathy) act alone or together (ie, neuromesenchymopathy or neuromyopathy), to cause severe dysmotility and related symptoms/signs in CIPO. Systemic disorders such as scleroderma, amyloidosis, and muscular dystrophies which can result in visceral myopathy may cause CIPO in affected patients. 14 Scleroderma is associated with increased systemic fibroblast proliferation and smooth muscle loss along the GI tract due to a chronic inflammatory process. 15 Amyloidosis plaque formation along the GI muscularis propria, mostly in the small bowel, by light chain protein and beta 2-microglobulin amyloid proteins can similarly result in intestinal pseudo-obstruction. 16 In contrast, amyloid A protein deposition is within the GI myenteric plexus, which results in neuronal disruption, and thus highlights the potential for a disease to have multiple affected components. Progressive hereditary skeletal muscle disorders such as myotonic dystrophy, Duchenne and oculophargyngeal muscular dystrophy, are examples of myopathic diseases, which are also associated with smooth muscle atrophy along the GI tract. 15 Smith et al 17 initially identified alpha actin absence within the circular muscular layer of the GI tract of a single CIPO patient, and Knowles et al 18 subsequently recognized this as potential biomarker for myopathic CIPO when 24% of study patients were found to have deficiency or absence of alpha actin. However, actin gene mutation is also seen in other disorders, such as megacystitis microcolon and intestinal hyperperistalsis syndrome, and therefore a definitive genotype-phenotype correlation is unable to be made at present. 19 Mesenchymopathy adversely impacts on interstitial cells of Cajal, where structural aberrations, deficiency or damage can subsequently result in impairment of intestinal motility regulation and therefore result in ineffective propulsion of GI content. 20 Neuropathy is considered to be amongst the most common causes of dysregulation leading to CIPO, which can be further subdivided into inflammatory or degenerative. 21 A multitude of conditions may result in inflammatory neuropathy, including autoimmune diseases and paraneoplastic syndromes, 15, 22 neurological disease and infections, whereby extensive lymphocytic, eosinophilic or mast cell infiltration in the neuromuscular compartment results in ganglionitis and/or leiomyositis disrupting signaling within the ENS. 3, 14 Degenerative neuropathy may be caused by endogenous and/or exogenous insults resulting in damage to the ENS mediated in part by a noninflammatory response, whose causes including mitochondrial dysfunction 23 where free radical formation leads to neuronal loss, radiation exposure and diabetes mellitus. 3 The pathological processes associated with CIPO are therefore numerous and varied, and a systematic approach is required to identify an underlying cause.
CLINICAL FEATURES
Clinical manifestations of CIPO are varied owing to its heterogenous etiology and diverse regional effects on the GI tract. A comprehensive history and examination is therefore required to assess the complex clinical features present in CIPO. Broadly speaking, clinical features can be categorized as direct, indirect or as complications.
Direct GI features mimic those of mechanical GI obstruction, where clinical features may broadly reflect the location and extent of GI involvement. In any age group, the most frequent symptoms and signs are abdominal pain (which is particularly severe during acute episodes) associated with bloating and distension. Upper GI involvement may cause nausea, vomiting, and weight loss, while more distal disease may result in diffuse abdominal pain, abdominal distension and constipation. 3 Esophageal involvement, which usually occurs in association with progressive systemic sclerosis, may cause symptoms of gastroesophageal reflux, dysphagia and/or odynophagia. 24 Clinical examination may reveal a succussion splash, a hypertympanic percussion note and occasionally intestinal loop contractions may be visible upon inspection of the abdomen. 2 Direct GI features mimicking obstruction typically present as recurrent subocclusive episodes characterized by sudden onset of intense pain, cramping, abdominal distension, nausea, and vomiting. 25 Although symptom onset may coincide with first subocclusive episode, patients more frequently have nonspecific and progressively worsening digestive symptoms for many years before diagnosis. 6 CIPO encompasses a wide spectrum of severity. With mild forms, patients may experience a relatively benign course with infrequent subocclusive episodes, asymptomatic intervals between episodes and nutritional supplementation seldom required. 6 Patients with more severe forms may experience recurrent painful subocclusive episodes requiring hospitalization, severe digestive symptoms between episodes and require parenteral nutritional support. 6, 24, 26 The severity of symptomatic progression depends on numerous factors including underlying etiology. 2 A range of indirect (extraintestinal) features may coexist in association with CIPO. Firstly, indirect features can provide indication of underlying systemic disease which may result in secondary CIPO. For example, proximal muscle weakness may indicate polymyositis or dermatomyositis. 1 Secondly, indirect features may represent coexisting pathology, which shares a similar underlying pathological process to CIPO. Urinary bladder dysfunction, for instance, frequently occurs in association with myopathic CIPO, which may cause incomplete bladder emptying and predispose to urinary tract infections. 11 Thirdly, certain indirect features occur specifically in syndromic forms of CIPO of which mitochondrial diseases predominate. These CIPO patients with mitochondrial disorders (eg, those with mitochondrial neurogastrointestinal encephalomyopathy) may present with neurological manifestations such as peripheral neuropathy with mild to moderate hypoesthesia, proprioceptive ataxia, progressive external ophthalmoplegia with ptosis and hearing loss in addition to severe intestinal dysmotility and poor nutritional status.
The main complications of CIPO include malnutrition, small intestinal bacterial overgrowth (SIBO), as well as those associated with surgical procedures. Malnutrition is a frequently encountered complication of CIPO and is associated with significant morbidity. 9 This is a particularly problematic aspect in the management of CIPO, particularly as the consumption of food may worsen GI symptoms resulting in food avoidance. 1 Patients with esophageal involvement may have reduced oral intake due to swallowing difficulties, and coexisting gastroparesis may cause early satiety as well as postprandial nausea and vomiting. 27 In the small intestine, impaired transit and chronically dilated bowel loops reduce nutrient absorption. 1 Furthermore, intestinal stasis may cause SIBO, resulting in diarrhea and steatorrhea, and subsequent malabsorption. 7 The severity of malnutrition in CIPO means that patients often require PN. 9 Surgery is frequently performed on patients with CIPO 6 as part of investigation for a mechanical obstruction, or as part of disease management. Adhesion formation as a complication from surgery predisposes patients to mechanical intestinal obstruction. Patients with CIPO who have adhesions following surgery may therefore present with mechanical obstruction on a background of pseudoobstruction, which inevitably complicates management. 3 As well as the physical complications, depression and other psychological disturbances may be present due to the frustration caused by ineffectiveness of most therapeutic interventions as well as the chronic nature of the disease. 3 A holistic approach is therefore required to assess and manage the diverse clinical features of CIPO.
Clinicians should also be aware that clinical features may differ between pediatric and adult patients with CIPO. In children, CIPO usually has an idiopathic etiology, most children are symptomatic by 12 months of age, and urinary involvement, colonic/small bowel volvulus and intestinal malrotation frequently co-exist. 7 In contrast, CIPO is secondary to another disease in approximately half of adult patients, diagnosis of CIPO is usually delayed by several years from symptom onset and coexisting symptoms in adults typically relate to the disease to which CIPO is secondary to. 1, 6, 7 
DIAGNOSTIC PROCEDURES
CIPO is an infrequently and inconsistently diagnosed condition due to its insidious onset and intermittency of nonspecific symptoms, a lack of awareness of the condition among clinicians, and the ambiguity of the diagnostic process. Following a thorough clinical assessment, further investigations are required to diagnose CIPO. At present, no single pathway exists as to guide clinicians how best to investigate CIPO. The 3 main principles of investigating CIPO include: (i) to confirm absence of GI mechanical obstruction; (ii) to identify underlying causes of secondary CIPO; (iii) to identify the character of disease and any complications present. 1 An integrated investigative approach utilizing radiology, endoscopy, laboratory, manometry, and histologic analysis is required.
Radiology
Radiologic investigations are key for investigating potential intestinal obstruction. Plain film x-rays are simple and inexpensive to perform, and may demonstrate the classic sign of dilated bowel loops with air-fluid levels (best seen in the erect film). However, abdominal x-rays cannot definitively distinguish between pseudo-obstruction and true mechanical intestinal obstruction 28 (Fig. 2) .
Subsequently, computerized tomography (CT) imaging of the abdomen provides more information to exclude an extraluminal, gut wall or intraluminal mechanically obstructive lesion. Although contrast follow-through studies such as CT-enterography may be useful in identifying gut wall aberrations which may be contributing or causative of an obstruction, issues with tolerability and flocculation of the contrast material limit their use in CIPO. 28 An emerging and radiation free method is cine-MRI, which has shown promise in recognizing poor small bowel contractility and at an earlier stage than that seen in CT imaging. 29 
Endoscopy
The main role of endoscopy in CIPO is to exclude mechanical obstruction within the foregut but also to facilitate biopsy collection for the exclusion of celiac disease. 21 Although colonoscopy is not a typical investigation required for CIPO diagnosis, it may be performed for therapeutic decompression in some patients. 30 More recently, Valli et al 31 demonstrated endoscopic full-thickness resection as a minimally invasive procedure to harvest a good quantity of tissue for histologic analysis where neuromuscular gut disorders are suspected.
Laboratory Tests
Once bowel obstruction has been excluded radiologically, laboratory tests can be used to identify secondary forms of CIPO related to potentially treatable disease such as endocrinopathies, which may be propagating CIPO. 7 In general, laboratory tests useful in the evaluation of a patient with CIPO may include: serum glucose (for diabetes mellitus); antitransglutaminase (for celiac disease); antinuclear antibodies (for autoimmune diseases); thyroid function tests (to investigate thyroid involvement); antineuronal nuclear antibodies (ANNA-1 or, based on their molecular target, anti-Hu) (to investigate paraneoplastic syndrome); antinuclear antibody, anti-double-stranded DNA and SCL-70, creatine phosphokinase, aldolase (for connective tissue and skeletal muscle disorders); serum lactic acid (at rest and during exercise), thymidine phosphorylase activity in the buffy coat, deoxyribonucleosides thymidine, and deoxyuridine (for mitochondrial neurogastrointestinal encephalomyopathy). In addition, patients on PN should be monitored for fluid and electrolyte balance and circulating levels of essential elements.
Manometry
Although small bowel manometry is not diagnostic of CIPO, it does have a role in providing an understanding of the underlying pathophysiology and differentiate CIPO from mechanical obstruction. 3 In particular, neuropathic dysfunction of the ENS and myopathy can be separated from mechanical obstruction. In the fasting period of manometry, in patients with an intrinsic neuropathy, uncoordinated sustained contractions of normal or increased amplitude (bursts) and/or abnormalities in the phase III activity front can be seen. 22 In contrast, low amplitude coordinated patterns are seen in patients with a myopathy. 22 In some cases, these low amplitude contractions may reflect the inability of dilated bowel loops to record lumen occluding contraction rather than a true myopathy. However, it should be noted that small bowel manometry is invasive and generally undertaken in specialized centers, as it requires a high degree of specialist interpretation. 32 In contrast to the above findings, mechanical obstruction presents with protracted episodes of large amplitude, nonpropagated contractions (clusters) which can be a useful distinguishing feature. Perez de Acre et al 33 recently reported findings from a retrospective study of 64 Chilean patients (age range, 13 to 76 y) with CIPO from 1995 to 2014. Small bowel manometry using a multilumen perfused catheter assembly was performed on all patients for at least 5 hours while fasted, conducted between a subocclusive crisis. Perez de Acre et and colleagues demonstrated that a very severe reduction of prolonged phasic waves as the explanation for reduction in luminal content propulsion, and that manometric findings were associated with mortality. Indeed, a third of the nine patients who died had absence of contractions and the rest had a severe myopathic character. 33 High-resolution esophageal manometry is of use in diagnosing scleroderma-related CIPO and high-resolution anorectal manometry for Hirschsprung disease, which may also require rectal biopsy for diagnostic confirmation. 34 Although findings can be pleomorphic, typical esophageal and anorectal manometric abnormalities are a hypotensive lower FIGURE 3. Representative photomicrographs comparing gut sections (ileum) of a 42-year female patient with a long history of chronic intestinal pseudo-obstruction (B) and a control case (a sex-age match case operated on for uncomplicated neoplastic disease of the right colon) (A). Note the clear-cut, readily detectable reduction of pan-neuronal marker labelled neuron-specific enolase (NSE) myenteric ganglia and neurons in the chronic intestinal pseudo-obstruction patient versus control. Jejunal laparoscopic biopsies were processed for indirect immunohistochemistry using a specific, ready-to-use anti-NSE rabbit polyclonal antibody (reference #PA1-28217, purchased from Thermo Fisher Scientific, Rockford, IL). Tissue biopsies were formalin fixed, paraffin embedded, cut with a microtome and finally processed with ABC-diaminobenzidine technique. Original magnification: ×100 in A and B.
esophageal sphincter with absent contractile activity and absence of the rectal anal inhibitory reflex, respectively. 35 Although manometry does not ultimately influence management, in the pediatric population it can be useful in prognostication and assessment potential response to enteral feeding.
Histology
Histologic analysis of intestinal tissue may provide useful information for the diagnosis of CIPO (Fig. 3) ; however, the precise utility and methods of tissue collection is still debated. With the establishment of minimal access surgery by means of laparoscopy, natural orifice, or endoscopic surgery, they lend to a less invasive method of tissue sampling with a good safety profile and high diagnostic yield. 36 It is also argued that laparotomy is preferable where mechanical obstruction is still suspected and subsequent full-thickness biopsy may be obtained. 21 Guidelines had been developed to support the safe acquisition of tissue, histologic techniques, reporting, and referral recommendations. 37 However there remains a lack of standardized practice in histopathologic methods which lead to conflicting definitions of normality which have hampered efforts in the identification of disease-specific pathologic patterns. 38 When tissue is acquired for histopathologic analysis the main abnormalities reflect the underlying category of the disorder for instance such as a neuropathic, myopathic or secondary pathology the latter of which may be attributable to an identifiable cause such as amyloidosis or systemic sclerosis. 39, 40 
CURRENT THERAPEUTIC OPTIONS
The effective management of CIPO is a challenge and is best undertaken in a multidisciplinary environment. Currently, the central objectives of treatment in CIPO are 5-fold: (a) patient education, (b) avoidance of unnecessary surgery, (c) to maintain an adequate caloric intake, limit malnutrition and avoid dehydration, (d) to promote coordinated GI motility, and (e) to treat symptoms and complications (eg, pain and SIBO, respectively), and in the case of secondary form of CIPO treating and managing the underlying disease. In general, current approaches remain far from effective and there is no specific treatment. 13 
Health Care Professional-patient Relationship and Patient Education
Central to improving outcomes in CIPO is the relationship between patients and health care professionals as part of a multidisciplinary team within an experienced and specialist center. The development of a therapeutic relationship and patient education are a central facet in the cornerstone of management. In this regard, peer support groups, such as the Pseudo-Obstruction Research Trust in the United Kingdom, online communities in social media and other similar groups, have an important role in providing peer support for patients and their families. Similarly, treatment options, and their underlying rationale and potential side effects, should be discussed in detail. The clinician and the patient should also agree upon, and set, reasonable treatment goals in the context of regular outpatient reviews. In this context, it is important not to underestimate the role of the wider multidisciplinary team, such as colleagues in psychiatry, psychology, dietetics, and social work services.
Nutritional Aspects
Suboptimal nutritional status is frequently seen in patients with CIPO largely due to 3 inter-related factors, which include malabsorption, insufficient caloric intake and the side effects of medications, particularly opioids. Generally speaking, CIPO patients with adequate intestinal absorption should be encouraged to ingest small volume but frequent meals and should avoid, where possible, dietary components that are high in fat and those with a high residue. Similarly food groups which are preferentially fermented, such those containing lactose, fructans, and fructose, should be avoided as they can worsen bloating and distension and may have a role in contributing to SIBO. 41 Where intake is suboptimal supplementation with liquid elemental feeds may be helpful. 42 Despite these conservative measures, a proportion of patients with CIPO will need further support with enteral feeding and a trial with nasogastric/ jejunal feeding maybe undertaken to supplement caloric intake. However, such tubes can be uncomfortable for the patient and can become displaced. If successful in allowing the patient to improve their nutritional status then consideration may be made at placing a percutaneous feeding tube either as a jejunostomy or a gastrostomy, the latter either with or without a jejunal extension. The placement of a feeding tube largely depends on the presence or absence of delayed gastric emptying, with ∼35% of patients with CIPO or severe functional GI disorders having gastroparesis. 43 When gastric emptying is delayed feeding should be jejunal, which is well tolerated in patients with manometrically demonstrable small migrating motor complexes (MMC). 13 When nutritional status becomes severely compromised, PN is indicated to deliver adequate hydration and nutrition. 42, 44 Should patients derived their nutritional solely from PN then they should receive in the order of 25 kcal/d of which 30% should be lipids in addition to protein of 1 to 1.5 g/kg/d with the remainder being made up by dextrose. 45 Although PN is associated with a number of complications include line sepsis, thrombosis, pancreatitis and liver failure, it is not associated with a significant increase in morbidity or mortality in CIPO. 9, 46 Pharmacological Therapy Numerous pharmacological therapies are used in CIPO to manage symptoms, promote propulsive GI motility and mange complications. Available data for use of pharmacological therapies to manage patients with CIPO is limited to case reports, small series and randomized-control trials with few participants in each arm. 7 This is because CIPO is a rare disease and a single center's gastroenterology department may care for only a few patients. 47 As such, there is a lack of clear evidence for effective pharmacological therapies for managing CIPO. As CIPO is a propulsive dysmotility disorder, prokinetic medications are recommended to be used; albeit based on limited CIPO-specific evidence. 42 Table 1 provides a summary of studies investigating prokinetic medications available for current practice to manage CIPO, and Table 2 provides a summary of the key pharmacological feature of each medication. Metoclopramide and domperidone are dopamine D2-receptor antagonists which have prokinetic effect at the upper GI tract and antiemetic properties. 63 Both of these dopamine antagonists are associated with QT-interval prolongation on electrocardiogram, 64 which requires monitoring if used long-term. In addition, metoclopramide is especially associated with extrapyramidal side effects (particularly in children, young adults, and the elderly) compared with domperidone due to more readily crossing the blood-brain barrier. 63 Indeed, the Food and Drug Administration (FDA) has issued metoclopramide with a "black-box" warning for tardive dyskinesia thus limiting its use. 65 Case reports of dopamine antagonists in CIPO have so far demonstrated mixed therapeutic results. 48, 50 Similarly, a case series of 11 CIPO patients over a 5-year period identified that while 2 patients had symptomatic response to metoclopramide (including postprandial nausea and vomiting), 2 other patients did not respond. 49 Little evidence therefore exists to demonstrate effectiveness of dopamine antagonists in the management of CIPO, and their side effects profile means they should be used with caution, especially long-term and in children, young adult, and elderly patients. 65 Erythromycin is a macrolide antibiotic which acts on motilin receptors located mainly in the upper GI tract, 66 thereby increasing antral contraction and promoting gastric emptying. As the effect of erythromycin on the small and large intestine is less clear, the role of erythromycin as a prokinetic agent is more established in gastroparesis than in CIPO. 47 Erythromycin may be given orally or intravenously using a dose typically lower than used as an antibiotic. 64 While early case reports suggested beneficial therapeutic effect of erythromycin in CIPO, 51, 52 more recent case series' have demonstrated a mixed response. One series investigated 12 adults (age range, 22 to 67 y) with CIPO of various etiology who had failed to response with other prokinetics including cisapride, domperidone and metoclopramide. 47 The patients were started on 1.5 to 2 g/d of erythromycin either orally or intravenously, with some patients later taking erythromycin on an "as required" basis. 47 Of the 12 patients, 6 responded (reported decreased severity and frequency of obstructive episodes) and 9 did not. Five (83%) of the responders were male compared with 2 (22%) of the nonresponders, 4 (67%) of the responders had a visceral myopathy diagnosis compared with 3 (33%) who failed to respond, and responders were less likely to use opiates long-term.
In a separate case series of 4 children (range, 11 to 14) with CIPO of varied etiology, 53 erythromycin (dose not specified) resulted in abdominal pain and distention resolution for 3 patients, while the 1 patient who did not respond to erythromycin later had symptom resolution with octreotide therapy. Erythromycin has been shown to elicit premature MMC phase III in normal subjects which propagate from the antrum to the upper small intestine, 67 but not in children with chronic functional GI disorders without fasting MMCs. 68 Furthermore, patients with neurogenic CIPO and severe GI dysmotility have been shown to have minimal motility response to erythromycin. 67 Side effects were not reported in either of the 2 case series investigating erythromycin. 47, 53 However, erythromycin inhibits cytochrome P450 and therefore interacts with medications metabolized by this pathway, and erythromycin, similar to the aforementioned dopamine antagonists, predisposes to QT-prolongation and subsequent risk, albeit small, of tachyarrhythmias and sudden cardiac death. 69, 70 As a potential alternative, azithromycin, which is a macrolide antibiotic with fewer side effects and does not interact with the cytochrome P450 enzymes, has been shown to induce more frequent antral activity fronts followed by duodenal contractions compared with erythromycin in patients with gastrointestinal dysmotility. 69 Long-term effectiveness of erythromycin is uncertain due to clinical responsiveness to oral administrations typically reducing after 4 weeks in patients with gastroparesis, but some patient may experience continued benefit beyond this time. 64 Although erythromycin therefore has evidence of benefit for some CIPO phenotypes, its long-term use is limited by its drug interaction, cardiac side effects, and primary effect at the upper GI tract with uncertain small intestine prokinetic effect. 47, 69 Octreotide is a long-acting somatostatin analogue that induces phase III of the MMC in the small intestine and is associated with antral motility inhibition. 71 As impaired gastric motility may induce or worsen gastroparetic symptoms, especially postprandially, nocturnal administration of octreotide is recommended if used. 72 The difference in site of prokinetic effect between octreotide and erythromycin has led to investigation of combination therapy in CIPO patients. Five of 14 CIPO patients reported improvement of nausea and abdominal pain over a mean 33-week follow-up while on a combination of octreotide 50 µg subcutaneously once at bedtime and erythromycin 200 mg orally administered 3 times daily. 57 Octreotide has also been investigated as a single-therapy. In a clinical trial of 5 adults with scleroderma-associated CIPO and SIBO, octreotide was shown to reduce breath hydrogen excretion (a proxy for SIBO) and improve digestive symptoms. 54 A case series of 3 patients (age range, 19 to 70 y) with CIPO secondary to connective tissue disease identified that while octreotide improved clinical symptoms (abdominal pain, distention, and vomiting) and manometric patterns, dose escalation was required to manage symptom recurrence. 55 A more recent case series of 16 total PN-dependent CIPO patients (age range, 1 to 18 y) demonstrated that octreotide at a dose range of 0.2 to 1 µg/kg/d divided into 2 doses increased tolerance to enteral feeds. 56 Side effects observed in 4 patients included allergic reaction, hyperglycemia, hypertension, and cholecystitis. 56 Anticholinesterase inhibitors (AChEI), such as neostigmine and pyridostigmine, act as prokinetics by increasing cholinergic synaptic transmission in the ENS. 60, 73 Neostigmine, a short-acting AChEI, is commonly used for patients with acute pseudo-obstruction who do not respond to conservative therapy. 74 A recent double-blind randomized placebo-controlled crossover study of 7 CIPO patients and 11 controls demonstrated that although the majority of CIPO patients responded to neostigmine, a reduced response was observed for the 3 patients with scleroderma. 59 Pyridostigmine, a longer-acting AChEI, has been investigated in a series of 4 CIPO patients (age range, 39 to 62 y). 60 Three of the patients had improved signs and symptoms with pyridostigmine while 1 patient had an initial response but later had surgery due to symptom recurrence. Although no side effects were reported for CIPO patients investigated with neostigmine and pyridostigmine, side effects of neostigmine frequently reported in patients with ACPO include abdominal pain, sialorrhea, vomiting, and bradycardia. 74 Serotonin 5-HT 4 receptors are present throughout the GI tract and 5-HT 4 antagonists primarily mediate their prokinetic effect through enhanced release of acetylcholine. 75 Cisapride, a partially selective 5-HT 4 agonist, had previously demonstrated effectiveness in CIPO management. 76, 77 However, reported deaths from cardiac arrhythmias related to cisapride's low selectivity meant it was removed from the market by the FDA in 2000. 78 Tegaserod, another partial 5-HT 4 agonists, had demonstrated evidence of accelerating GI motility 79, 80 but was withdrawn in 2007 by the FDA following concern over increased risk of cardiovascular ischemic events. 81 However, a cohort study with over 50,000 tegaserod initiators and matched comparators has since found no increased risk. 81 Highly selective 5-HT 4 agonists have more recently been investigated to avoid the cardiovascular side effect profile of other serotonin agonists. Prucalopride, a highly selective serotonin 5-HT 4 agonist capable of increasing whole-gut transit, has been investigated in a multiple n-of-1 trial with 4 CIPO patients (3 visceral myopathy and 1 visceral neuropathy). 61 Prucalopride 2 to 4 mg or placebo daily for four 12-week treatment periods significantly improved pain in 3 patients, nausea in 2, vomiting in 1, bloating in 4, and reduced analgesic intake in the 2 patients using rescue analgesia during the study; however, bowel function did not substantially change. Although 3 subjects reported adverse events, these were not attributed to prucalopride. 61 Abdominal pain can be severe and is often intractable in CIPO. 82 Patients may subsequently be managed with opioids 6 resulting in constipation and thus worsening of digestive symptoms. 3 Clinicians should therefore be aware of the side effect profile of analgesic agents used and manage them accordingly.
SIBO is related to GI dysmotility with 1 study including 80 patients with dysmotility identifying 61 (76%) patients with small bowel bacterial and/or fungal overgrowth. 83 Investigation for SIBO may include small intestinal aspiration and culture, breath-testing technique, or a therapeutic trail of antibiotic approach; however, each method is associated with limitations and there is no "gold standard." 84 SIBO treatment with antibiotics aims to modify the enteric dysbiosis, with numerous different antibiotic regimes recommended despite lack of consensual approach. 84 Rifaximin, a poorly entericabsorbed antibiotic to avoid systemic adverse effects and with broad-spectrum antibacterial activity, has been suggested to be effective and safe for the treatment of SIBO. 85 Immunosuppressive therapy with corticosteroids or immunosuppressants may play a role in treating forms of CIPO in which an inflammatory neuropathy (myenteric ganglionitis)/ myopathy (leiomyositis) has been proven histologically. However, the outcome of immunosuppressive therapy in inflammatory neuromyopathies is largely dependent on the degree of neuromuscular damage at the time therapy is started.
ENDOSCOPIC AND SURGICAL THERAPY
The aim of endoscopic or surgical therapy is to provide relief from obstructive symptoms caused by dilated GI segments while also sustaining nutritional status. Decompression permits improved alimentary transport, as well as decreased frequency of hospital admissions and need for surgery. 86 Nasogastric tubes, rectal, and endoscopic deflation provide effective therapy to address this. 1, 21 The use of "venting" enterostomies also provide a safe and effective management option to achieve this, with the added option of feeding depending on the stoma site. [87] [88] [89] In a more recent study, percutaneous endoscopic gastro-jejunostomy has been shown to decrease symptom frequency and improve nutritional status in CIPO patients, although clearly such nutritional efforts may be limited in patients with limited motility in the foregut and midgut. 90 CIPO patients may undergo multiple surgical procedures over the course of their lifetime, yet the therapeutic benefits of this are highly controversial. As described above, surgery is a useful method by which full-thickness bowel specimens may be acquired for histology; however, its most notable role is within the acute presentation of marked bowel dilatation, ischemia or bowel perforation. 7 When successful, surgery may provide symptomatic relief and a reduction in frequency of hospital admissions. 86 For those with progressive disease recalcitrant to medication it may confer effective palliation, maintain patient nutritional status alongside PN, and increase patient quality of life. 91 However, surgery increases the risk of the formation of adhesions which in itself is responsible for > 40% of all intestinal obstruction cases, 92 and may further complicate CIPO. In 1 study, surgical morbidity was shown to be 58.2% leading to reoperation in 17% of cases, and after initial surgery further CIPO related reoperation was 66% at 5 years. 93 Therefore, any resectional procedures should be highly selective as CIPO may progressively affect any segment of the GI tract, thereby providing only temporary benefit and may conversely cause clinical deterioration due to surgical risk factors as well as increased malnutrition. 94, 95 
Transplantation
In patients who develop serious complications of PN, such as recurrent sepsis, liver failure or loss of venous access, visceral transplantation can be considered. Although optimal terminology is controversial, visceral transplantation may include isolated small bowel transplantation, modified multivisceral transplantation (intestine and stomach without a liver graft) and multivisceral transplant (intestine plus stomach and liver; pancreas included for technical reasons). 96 Although removal of the native stomach may be required in patients with CIPO due to delayed gastric emptying, this has not shown to eliminate gastric dysmotility. 97, 98 To date, motility disorders account for 18% of intestinal transplantations in children and 11% in adults. 96 Patient survival for intestinal transplantation since 2000 has been reported as 77% at 1 year, 58% at 5 years and 47% at 10 years. 96 
FUTURE DIRECTIONS Diagnostics
Manometry is invasive and can be poorly tolerated. Furthermore, antroduodenal manometry is not standardized among centers which limits its use. The wireless motility capsule is a minimally invasive technology that detects intraluminal pH, temperature and pressure as it traverses the GI tract. 99 Moreover, there are established normal values for transit times and contractility data using this technology. 100, 101 However, in patients with CIPO there is a risk of capsule retention, which is reported in up to 21% in patients with mechanical intestinal obstruction. 102 Potentially using a patency capsule ab initio could mitigate this risk. MRI is an emerging noninvasive tool in the CIPO diagnostic work up. Studies have shown promising results in assessing the dysmotility and its correlation with the current standard, intestinal manometry, is awaited. We await prospective studies to help clarify the use of full-thickness biopsy in CIPO, and whether it aids in clinical decision making to improve outcomes. In particular, where clear secondary pathologic processes have already been established invasive investigation are not needed as the neuromuscular pathologic basis of CIPO is already well established. Furthermore, while the London Classification of GI neuromuscular disorders has improved standardization in the reporting of histologic specimens, such classifications need to be used more widely. 37 
Therapy
In other disorders characterized by abdominal pain and an alteration in GI motility, such as irritable bowel syndrome, reduction in the consumption of fermentable oligosaccharide, disaccharide, and monosaccharide and polyols
